anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study investigated the mechanism by which NR4A1 regulates mitochondrial fission factor (Mff)-related mitochondrial fission and FUN14 domain 1 (FUNDC1)-mediated mitophagy following cardiac ischemia-reperfusion injury(I/R). Our findings showed that the damage regulation was positively correlated with the pathological fission and pan-apoptosis of myocardial cell mitochondria. Compared with wild-type mice (WT), NR4A1-knockout mice exhibited resistance to myocardial ischemia-reperfusion injury and mitochondrial pathological fission, characterized by mitophagy activation. Results showed that ischemia-reperfusion injury increased NR4A1 expression level, activating mitochondrial fission mediated by Mff and restoring the mitophagy phenotype mediated by FUNDC1. The inactivation of FUNDC1 phosphorylation could not mediate the normalization of mitophagy in a timely manner, leading to an excessive stress response of unfolded mitochondrial proteins and an imbalance in mitochondrial homeostasis. This process disrupted the normalization of the mitochondrial quality control network, leading to accumulation of damaged mitochondria and the activation of pan-apoptotic programs. Our data indicate that NR4A1 is a novel and critical target in myocardial I/R injury that exertsand negative regulatory effects by activating Mff-mediated mito-fission and inhibiting FUNDC1-mediated mitophagy. Targeting the crosstalk balance between NR4A1-Mff-FUNDC1 is a potential approach for treating I/R.
Accidental exposure to high-dose radiation while pregnant has shown significant negative effects on the developing fetus. One fetal organ which has been studied is the placenta. The placenta performs all essential functions for fetal development, including nutrition, respiration, waste excretion, endocrine communication, and immunological functions. Improper placental development can lead to complications during pregnancy, as well as the occurrence of intrauterine growth-restricted (IUGR) offspring. IUGR is one of the leading indicators of fetal programming, classified as an improper uterine environment leading to the predisposition of diseases within the offspring. With numerous studies examining fetal programming, there remains a significant gap in understanding the placenta's role in irradiation-induced fetal programming. This review aims to synthesize current knowledge on how irradiation affects placental function to guide future research directions. This review provides a comprehensive overview of placental biology, including its development, structure, and function, and summarizes the placenta's role in fetal programming, with a focus on the impact of radiation on placental biology. Taken together, this review demonstrates that fetal radiation exposure causes placental degradation and immune function dysregulation. Given the placenta's crucial role in fetal development, understanding its impact on irradiation-induced IUGR is essential.
Acute kidney injury (AKI) is a common critical condition with high morbidity and mortality. Not only can AKI cause death in the acute phase, but also can it be associated with the development of chronic kidney disease (CKD) or the progression of CKD. Galectins are members of a lectin family widely expressed in vertebrates, among which galectin-3 (Gal3) is the most studied one. The level of circulating Gal3 largely depends on renal function, so it is elevated in patients with AKI or CKD; elevated Gal3 also aggravates the progression of CKD after the onset of AKI. The proinflammatory and profibrotic properties of Gal3 may render it to be one of the key molecules mediating AKI, CKD, and cardiorenal syndrome. However, the mechanisms of AKI differ from different etiologies, and the process and extent of levels of Gal3 may be also different, so its predictive value in prognosis may vary in different types of AKI. In critically ill patients, AKI is a common complication of sepsis, and sepsis is the most common trigger of AKI. In this prospective observational study, the investigators will explore the differences of Gal3 levels among septic AKI, non-septic AKI, and non-AKI patients and its correlation with prognosis, inflammation, and disease severity in the ICU.
<P>PROBLEM TO BE SOLVED: To obtain a composition for the oral cavity, which prevents and ameliorates periodontal disease.  <P>SOLUTION: The composition for the oral cavity is obtained by mixing an extract derived from a crude medicine, having hemostatic and/or antiphlogistic and anti-inflammatory effect with a propolis extract. The crude medicine is a plant belonging to the genus Daucus of the family Araliaceae. The plant is Denshichi Ginseng. The amount of the crude medicine mixed is 0.01-15.0 wt.%. The amount of the propolis extract mixed is 0.01-10.0 wt.%. A plant body itself, leaves, stems, rhizomes, roots, etc., may be cited as a part to be used for obtaining the material derived from the crude medicine. One or more of them are used alone or together. Among them, the roots are preferable due to containing a large amount of a triterpene-based saponin.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The network will create a large-scale clinicogenomics dataset, which will support research to discover molecular and genetic determinants of disease risk, disease progression, treatment response, health economic outcomes, social or behavioral determinants of health, targets for therapeutic intervention, risk stratification, clinical implementation, and other clinical indicators of interest. This clinicogenomics dataset will be used to reveal molecular and/or genetic factors that could improve the diagnosis or medical treatment of individual participants and includes a process to share individual results with participants. Participants will also receive annual reports on study outcomes and the impact of HRN, as such information becomes available.

Institutional membership in HRN will consist of Helix and member healthcare systems (herein referred to as "HRN Member Site(s)"). The Helix Research Network is a multi-center research program that will enroll an unlimited number of participants. Participants will be recruited concurrently from HRN Member Sites. In some cases, HRN Member Sites may recruit participants from multiple clinical sites. Participants who meet the enrollment criteria established in this protocol will be enrolled if they or their legally authorized representative(s) provide informed consent in accordance with all applicable regulations and sIRB requirements. Participants will be enrolled until withdrawal from the study or end of the study. Participants may be recruited at any point during the study period, until the recruitment goals established by the protocol are met.
Mycoplasma infection in animals is combatted by feeding non-human animals (e. g. poultry) with a non-toxic feed contg. a safe, but effective amount of a cpd. I: (each R is 1-3C alkyl, pref. the same) e. g. 30-80 ppm I for poultry less than 1 week old increasing to 80-200 ppm I for poultry 1 week or more old. The feeding is continued pref. for at least 30 days. Suitably in the first week poultry are fed on a feed contg. 30-40 ppm I and in the second and following weeks the amount is increased to 80-200 ppm.
BACKGROUND: Atherosclerotic (AS) plaques require a dense necrotic core and a robust fibrous cap to maintain stability. While previous studies have indicated that the traditional Chinese medicine Huang Lian Jie Du Decoction (HLJDD) possesses the capability to stabilize AS plaques, the underlying mechanisms remain obscure. This study aims to delve deeper into the potential mechanisms by which HLJDD improves AS through an integrated research strategy.
METHODS: Leveraging an AS model in ApoE-/- mice exposed to a high-fat diet (HFD), we scrutinized the therapeutic effects of HLJDD using microscopic observations, oil red O staining, HE staining and Masson staining. Employing comprehensive techniques of network pharmacology, bioinformatics, and molecular docking, we elucidated the mechanism by which HLJDD stabilizes AS plaques. In vitro experiments, utilizing ox-LDL-induced macrophages and apoptotic vascular smooth muscle cells (VSMCs), assessed the impact of HLJDD on efferocytosis and the role of SLC2A1.
RESULTS: In vivo experiments showcased the efficacy of HLJDD in reducing the quantity of aortic plaques, diminishing lipid deposition, and enhancing plaque stability in AS mice. Employing network pharmacology and machine learning, we pinpointed SLC2A1 as a crucial regulatory target. Molecular docking further validated the binding of HLJDD components with SLC2A1. The experiments demonstrated a dose-dependent upregulation in SLC2A1 expression by HLJDD, amplifying efferocytosis. Importantly, this effect was reversed by the SLC2A1 inhibitor STF-31, highlighting the pivotal role of SLC2A1 as a target.
CONCLUSION: The HLJDD can modulate macrophage efferocytosis by enhancing the expression levels of SLC2A1, thereby improving the stability of atherosclerotic plaques.
Participants randomized to the imiquimod + 9-valent HPV vaccine group will receive instruction on imiquimod self application (16 week course) at the baseline visit. In addition, all women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
Patients who have not had adequate blood count recovery post related or unrelated stem cell transplant will be given a "boost" of T-cell depleted, enriched stem cells to hopefully improve their blood counts.

The unrelated donors will receive G-CSF prior to pheresis (collection of the stem cells) to boost the number of CD34+ cells. The related donors will receive G-CSF and AMD3100 prior to pheresis to boost the number of CD34+ cells. Once the CD34+ cells are collected they will be T-cell depleted using a cell separation device called the CliniMACS systems. The CliniMACS system will select the CD34+ cell and remove the T-cells. By removing the T-cells we can minimize the risk of Graft Versus Host Disease (GVHD). The enriched CD34+ cells will be given to them to hopefully give them a "boost" of cells that can permanently produce new blood cells to improve their risk of infection and bleeding.
Peripheral arterial disease (PAD) patients with critical limb-threatening ischemia have improved peripheral circulation following infrainguinal revascularization. Despite this hemodynamic benefit, little change in functional status occurs, and many patients have residual ambulatory dysfunction. The lack of functional improvement in revascularized patients may be due to extreme physical deconditioning secondary to their pre-existing critical limb-threatening ischemia. Therefore, we hypothesize that a program of aerobic exercise training is necessary to optimize ambulation, free-living daily physical activity, and health-related quality of life through the mechanisms of improved walking economy, peripheral circulation, and cardiopulmonary function.

This is a prospective, randomized controlled clinical trial comparing an exercise group undergoing a program of graded treadmill walking, and a non-exercise control group. Eighty PAD patients will be randomized into either the exercise group (N = 40) or the non-exercise control group (N = 40) following successful lower extremity arterial bypass or angioplasty. The 3-month exercise program will consist of graded treadmill walking 3 times per week with progressive increments in exercise duration from 15 to 40 minutes, and progressive increments in exercise intensity from 50 to 80% of exercise capacity.
The global public health emergency of COVID-19 in January 2020 prompted a surge in research focusing on the pathogenesis and clinical manifestations of the virus. While numerous reports have been published on the acute effects of COVID-19 infection, the review explores the multifaceted long-term implications of COVID-19, with a particular focus on severe maternal COVID-19 infection, gut microbiome dysbiosis, and neurodevelopmental disorders in offspring. Severe COVID-19 infection has been associated with heightened immune system activation and gastrointestinal symptoms. Severe COVID-19 may also result in gut microbiome dysbiosis and a compromised intestinal mucosal barrier, often referred to as 'leaky gut'. Increased gut permeability facilitates the passage of inflammatory cytokines, originating from the inflamed intestinal mucosa and gut, into the bloodstream, thereby influencing fetal development during pregnancy and potentially elevating the risk of neurodevelopmental disorders such as autism and schizophrenia. The current review discusses the role of cytokine signaling molecules, microglia, and synaptic pruning, highlighting their potential involvement in the pathogenesis of neurodevelopmental disorders following maternal COVID-19 infection. Additionally, this review addresses the potential of probiotic interventions to mitigate gut dysbiosis and inflammatory responses associated with COVID-19, offering avenues for future research in optimizing maternal and fetal health outcomes.
The invention discloses a swine transmissible gastroenteritis virus (TGEV) antigen fusion gene, a recombinant bacillus megaterium strain and application. The invention provides an antigen fusion gene obtained by connecting a swine transmissible gastroenteritis virus Sad sequence and a streptococcus pyogenes cell wall anchoring sequence, and a nucleotide sequence of the antigen fusion gene is shown as SEQ ID No. 1. The invention further provides a recombinant expression vector containing the antigen fusion gene and the recombinant bacillus megaterium strain containing the recombinant expression vector. The recombinant bacillus megaterium strain is induced by using xylose, and the antigen fusion gene can be expressed on the surface of the bacterial cell wall. Immunoblotting experiments indicate that the expressed recombinant protein can react with TGEV immune serum and has the same antigenicity as TGEV natural antigens, and the recombinant protein can be prepared into safe and effective mucous immune live vaccines for preventing and treating swine transmissible gastroenteritis.
Patients in Group TCIS (target-controlled infusion sedation) received IV propofol via a target-controlled infusion (TCI) pump, targeted at an initial effect site concentration (Cet) of 0.6 μg/ml, using the Schnider pharmacokinetic model. Upon attainment of 0.6 μg/ml Cet, the patient's sedation level was assessed. The Cet was increased or reduced accordingly by 0.2 μg/ml to attain an OAA/S score of 3.
PURPOSE:To obtain a bacterium-derived hypotensor having low side effects, readily usable, containing an extract of a cell of lactic acid bacillus with water as an active ingredient. CONSTITUTION:A cell of lactic acid bacillus (e.g. Lactobacillus casei, L. plantarum, etc.) is suspended in water at >=50 deg.C in 10-80mg/ml and extracted under a preferable condition for 10-60min. After the extraction is over, the cell, an insoluble substance comprising fragments thereof, etc., are removed to give an extracted solution, which is concentrated as it is and dried to give a hypotensor. Salts and other low-molecular weight substances are removed to give the more effective hypotensor (main components are 37% saccharide, 15% protein and 32% nucleic acid; yield is 10mg based on 100mg dried cell). The hypotensor can be readily made into any dosage form and can be administered orally (including sublingual administration) or parenterally (intravenous injection, intravenous drip, etc.).
The present invention discloses an ambroxol hydrochloride drop pill and a preparation method thereof. Main components of medicine comprise ambroxol hydrochloride fine powder which is pulverized in an ultrafine mode, and molten basal materials. The preparation method comprises the steps that the ambroxol hydrochloride fine powder which is pulverized in an ultrafine mode is added to the molten basal materials; the ambroxol hydrochloride fine powder and the molten basal materials are mixed evenly and are dripped into coolant by a dripping method to be cooled into pills; the coolant is removed; the pills are dried. The present invention is obtained. The drop pill of the present invention has the advantages of short disintegration time, high dissolution degrees and biological availability, and stable quality. The volume of the pill is small. The present invention not only can be swallowed, but also can be kept in mouth. The present invention can be carried and taken conveniently. Moreover, the present invention can take effect rapidly with good compliance and higher therapeutic effect. The present invention is particularly suitable for children, sickbed patients and dysphagia patients to take.
The invention relates to a traditional Chinese medicine preparation for treating anemia. The preparation is characterized by being prepared from the herbal medicines such as astragalus membranaceus processed with honey, sealwort, caulis spatholobi and salviae miltiorrhizae. The preparation comprises dosage forms of granules, troches, capsules, oral liquids and the like and has the functions of tonifying qi and blood and enriching and nourishing blood. The total effect rate of the preparation for clinically treating 20 cases of anemia is 90.00%, wherein 4 cases are basically restored and 9 cases are remarkably improved. The preparation can be used for remarkably improving symptoms of anemia, particular anemia induced by insufficiency of qi in stomach, spleen and kidneys. The clinical symptoms such as feeble limbs, pale complexion, palpitation, dizziness, tinnitus, dreaminess and anorexia are remarkably improved relatively.
Asthma is a widespread airway disorder where GATA3-dependent Type-2 helper T (Th2) cells and group 2 innate lymphoid cells (ILC2s) play vital roles. Asthma-associated single nucleotide polymorphisms (SNPs) are enriched in a region located 926-970 kb downstream from GATA3 in the 10p14 (hG900). However, it is unknown how hG900 affects the pathogenesis of allergic airway inflammation. To investigate the roles of the asthma-associated GATA3 enhancer region in experimental allergic airway inflammation, we first examined the correlation between GATA3 expression and the activation of the hG900 region was analyzed by flow cytometry and ChIP-qPCR. We found that The activation of enhancers in the hG900 region was strongly correlated to the levels of GATA3 in human peripheral T cell subsets. We next generated mice lacking the mG900 region (mG900KO mice) were generated by the CRISPR-Cas9 system, and the development and function of helper T cells and ILCs in mG900KO mice were analyzed in steady-state conditions and allergic airway inflammation induced by papain or house dust mite (HDM). The deletion of the mG900 did not affect the development of lymphocytes in steady-state conditions or allergic airway inflammation induced by papain. However, mG900KO mice exhibited reduced allergic inflammation and Th2 differentiation in the HDM-induced allergic airway inflammation. The analysis of the chromatin conformation around Gata3 by circular chromosome conformation capture coupled to high-throughput sequencing (4C-seq) revealed that the mG900 region interacted with the transcription start site of Gata3 with an influencing chromatin conformation in Th2 cells. These findings indicate that the mG900 region plays a pivotal role in Th2 differentiation and thus enhances allergic airway inflammation.
PURPOSE: A health food composition for improving dementia is provided to cleanse pulmonary alveolus, supply oxygen to the brain, cleanse cerebral blood vessels, and intensify circulation function to cleanly increase blood in cerebral blood vessels. CONSTITUTION: A health food composition for improving dementia comprises an extract of two or more selected from pine rootlets, Tricholoma matsutake, pine nuts, Gastrodiae rhizome, and schizandra. The extract of mixture is comprised with 0.001-10 wt% of each thereof according to the total composition weight. Based on a dried weight of the composition mixture, 1-40 weight% of pine rootlets, 1-40 weight% of pine nuts, 1-40 weight% of Gastrodiae rhizome, or 1-40 weight% of schizandra are included. The health food composition may be in a form of one or more selected from a pill, granules, a soft capsule agent, a hard capsule agent, syrup, a beverage, a soft extract, a dry extract, a double boiled liquid, and an extracted double boiled liquid. The extract may be extracted by water, an organic solvent, or a mixture thereof. The organic solvent may be an alcoholic solvent of carbon number 1-4. The organic solvent may be one or more selected from methanol, ethanol, propyl alcohol, butyl alcohol, glycerine propylene glycol, and butylene glycol.
<P>PROBLEM TO BE SOLVED: To provide an image interpretation support system and a program which can improve efficiency of an image interpretation diagnostic work and understanding of a medical examinee regarding the diagnosis or the image interpretation.  <P>SOLUTION: An image read in from a hard disc 9 is displayed on an image display device 15. A CPU 5 of a controller 3 records the displayed image in time series as image information Vn, and at the same time, it records voices inputted by a voice inputting device 21 in time series as voice information S. The start and the finish of the recording are controlled by a button 23. The CPU 5 generates composition data 300 by composing the image information Vn and the voice information S, which are recorded in time series, by making them to correspond to each other in time series when the recording is finished. An external recording device 25 records the composition data 300 in a medium 31.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The HH group will observe the dietary guidelines in compliance with the National Cholesterol Education Program Therapeutic Lifestyle Changes (TLC) diet. This diet consists of consuming \<35% of kcal as fat; 50%-60% of kcal as carbohydrates; \<200 mg/dL of dietary cholesterol; and 20-30 g/day of fiber. The total calorie intake will be 1200 and 1500 calories per day, women and men, respectively during the weight loss phase (weeks 0-8).
RATIONALE: Bladder carcinosarcoma (BC) is a malignant tumor composed of a mixture of malignant epithelial and stromal components. Carcinosarcoma mostly occurs in the upper respiratory tract and upper gastrointestinal tract and is less common in the urinary system. The incidence of malignant tumors of the urinary system is <3%. It rarely occurs in the bladder and accounts for approximately 0.31% of all malignant bladder tumors. A literature review and this report will help to further improve our understanding, diagnosis, and treatment of bladder carcinosarcoma (BC).
PATIENT CONCERN: We describe the case of an 80-year-old female patient who was admitted to the hospital with a history of intermittent hematuria for 3 years. Furthermore, total cystectomy was refused when a BC was diagnosed. Palliative resection surgery was necessary because of the recurrent hematuria and abdominal pain.
DIAGNOSES: Pathologically confirmed BC after surgery.
INTERVENTIONS: The patient's first transurethral resection of bladder tumor (TURBT) was diagnosed as BC. However, the patient refused a total cystectomy. Two months after intravesical treatment with epirubicin, bladder tumor recurrence was observed during follow-up cystoscopy. The patient underwent a second TURBT for hemostatic treatment due to persistent hematuria. Due to hematuria and abdominal pain, a third TURBT was performed to reduce tumor size and stop bleeding. Finally, tumor recurrence resulted in bilateral hydronephrosis, and the patient underwent bilateral renal catheter drainage guided by B-ultrasound.
OUTCOMES: Bladder carcinosarcoma caused uremia, electrolyte imbalance, and sepsis. Approximately 19 months after the discovery of the tumor, the patient died.
LESSONS: Radical bladder resection is recommended once a BC is diagnosed. By reporting the cases and reviewing the literature in the database, we will summarize the epidemiology, origin, etiology, clinical features, existing treatments, and prognostic factors of BC, and propose new prospects for BC therapy.